Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) - Total Assets
Based on the latest financial reports, Starlake Bioscience Co Inc Zhaoqing Guangdong (600866) holds total assets worth CN¥17.39 Billion CNY (≈ $2.54 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Starlake Bioscience Co Inc Zhaoqing Guan cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Starlake Bioscience Co Inc Zhaoqing Guangdong - Total Assets Trend (1994–2025)
This chart illustrates how Starlake Bioscience Co Inc Zhaoqing Guangdong's total assets have evolved over time, based on quarterly financial data. See 600866 net asset value for net asset value and shareholders' equity analysis.
Starlake Bioscience Co Inc Zhaoqing Guangdong - Asset Composition Analysis
Current Asset Composition (December 2025)
Starlake Bioscience Co Inc Zhaoqing Guangdong's total assets of CN¥17.39 Billion consist of 34.0% current assets and 66.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 12.7% |
| Accounts Receivable | CN¥625.62 Million | 3.6% |
| Inventory | CN¥2.21 Billion | 12.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥662.84 Million | 3.8% |
| Goodwill | CN¥29.32 Million | 0.2% |
Asset Composition Trend (1994–2025)
This chart illustrates how Starlake Bioscience Co Inc Zhaoqing Guangdong's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Starlake Bioscience Co Inc Zhaoqing Guan (600866) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Starlake Bioscience Co Inc Zhaoqing Guangdong's current assets represent 34.0% of total assets in 2025, a decrease from 46.3% in 1994.
- Cash Position: Cash and equivalents constituted 12.7% of total assets in 2025, up from 0.0% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 1994.
- Asset Diversification: The largest asset category is inventory at 12.8% of total assets.
Starlake Bioscience Co Inc Zhaoqing Guangdong Competitors by Total Assets
Key competitors of Starlake Bioscience Co Inc Zhaoqing Guangdong based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Prostemics Co. Ltd
KQ:203690
|
Korea | ₩39.70 Billion |
|
ORUM
KQ:475830
|
Korea | ₩191.52 Billion |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
TG Therapeutics Inc
NASDAQ:TGTX
|
USA | $1.53 Billion |
|
Green Cross Holdings Preference Shares
KO:005257
|
Korea | ₩4.12 Trillion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
|
Cybin Inc
NEO:CYBN
|
Canada | CA$290.11 Million |
Starlake Bioscience Co Inc Zhaoqing Guangdong - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.97 | 1.14 | 1.48 |
| Quick Ratio | 0.49 | 0.75 | 0.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-175.68 Million | CN¥835.03 Million | CN¥274.86 Million |
Starlake Bioscience Co Inc Zhaoqing Guangdong - Advanced Valuation Insights
This section examines the relationship between Starlake Bioscience Co Inc Zhaoqing Guangdong's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.23 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 18.5% |
| Total Assets | CN¥17.24 Billion |
| Market Capitalization | $1.08 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Starlake Bioscience Co Inc Zhaoqing Guangdong's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Starlake Bioscience Co Inc Zhaoqing Guangdong's assets grew by 18.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Starlake Bioscience Co Inc Zhaoqing Guangdong (1994–2025)
The table below shows the annual total assets of Starlake Bioscience Co Inc Zhaoqing Guangdong from 1994 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥17.24 Billion ≈ $2.52 Billion |
+18.49% |
| 2024-12-31 | CN¥14.55 Billion ≈ $2.13 Billion |
+1.15% |
| 2023-12-31 | CN¥14.38 Billion ≈ $2.10 Billion |
-10.09% |
| 2022-12-31 | CN¥16.00 Billion ≈ $2.34 Billion |
+546.83% |
| 2021-12-31 | CN¥2.47 Billion ≈ $361.93 Million |
+2.12% |
| 2020-12-31 | CN¥2.42 Billion ≈ $354.41 Million |
+14.45% |
| 2019-12-31 | CN¥2.12 Billion ≈ $309.67 Million |
+46.42% |
| 2018-12-31 | CN¥1.45 Billion ≈ $211.50 Million |
-0.23% |
| 2017-12-31 | CN¥1.45 Billion ≈ $211.99 Million |
-15.30% |
| 2016-12-31 | CN¥1.71 Billion ≈ $250.27 Million |
-7.25% |
| 2015-12-31 | CN¥1.84 Billion ≈ $269.83 Million |
-18.25% |
| 2014-12-31 | CN¥2.26 Billion ≈ $330.05 Million |
-13.37% |
| 2013-12-31 | CN¥2.60 Billion ≈ $381.01 Million |
-21.87% |
| 2012-12-31 | CN¥3.33 Billion ≈ $487.67 Million |
-2.62% |
| 2011-12-31 | CN¥3.42 Billion ≈ $500.81 Million |
+48.34% |
| 2010-12-31 | CN¥2.31 Billion ≈ $337.62 Million |
+54.06% |
| 2009-12-31 | CN¥1.50 Billion ≈ $219.15 Million |
+10.37% |
| 2008-12-31 | CN¥1.36 Billion ≈ $198.56 Million |
+0.56% |
| 2007-12-31 | CN¥1.35 Billion ≈ $197.45 Million |
-4.24% |
| 2006-12-31 | CN¥1.41 Billion ≈ $206.19 Million |
+3.27% |
| 2005-12-31 | CN¥1.36 Billion ≈ $199.66 Million |
+4.61% |
| 2004-12-31 | CN¥1.30 Billion ≈ $190.85 Million |
+11.34% |
| 2003-12-31 | CN¥1.17 Billion ≈ $171.41 Million |
+14.41% |
| 2002-12-31 | CN¥1.02 Billion ≈ $149.82 Million |
+2.22% |
| 2001-12-31 | CN¥1.00 Billion ≈ $146.56 Million |
-7.51% |
| 2000-12-31 | CN¥1.08 Billion ≈ $158.47 Million |
+27.80% |
| 1999-12-31 | CN¥847.38 Million ≈ $124.00 Million |
+38.06% |
| 1998-12-31 | CN¥613.79 Million ≈ $89.82 Million |
+20.14% |
| 1997-12-31 | CN¥510.92 Million ≈ $74.76 Million |
+32.59% |
| 1996-12-31 | CN¥385.33 Million ≈ $56.39 Million |
+7.24% |
| 1995-12-31 | CN¥359.32 Million ≈ $52.58 Million |
+11.34% |
| 1994-12-31 | CN¥322.72 Million ≈ $47.22 Million |
-- |
About Starlake Bioscience Co Inc Zhaoqing Guangdong
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong engages in the manufacture and sale of pharmaceutical raw materials, and food and feed additives under the Star Lake and Yue Bao brand names in China and internationally. The company offers L-proline for use as an intermediate for synthesizing captopril and enalapril, and raw material for amino acid transfusion; guanosine that is used as an interme… Read more